{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T15:05:42Z","timestamp":1778511942351,"version":"3.51.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,25]],"date-time":"2020-04-25T00:00:00Z","timestamp":1587772800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,4,25]],"date-time":"2020-04-25T00:00:00Z","timestamp":1587772800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>In this meta-analysis, we aimed to systematically compare the post percutaneous coronary interventional (PCI) adverse bleeding events, stent thrombosis, stroke and other cardiovascular outcomes in a population of patients with and without thrombocytopenia at baseline who were followed up on dual antiplatelet therapy (DAPT).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Relevant English language articles which were published before June 2019 were retrieved from MEDLINE, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.clinicaltrials.com\">http:\/\/www.ClinicalTrials.com<\/jats:ext-link>, EMBASE, Cochrane central, and Google scholar briefly using specific terms such as percutaneous coronary intervention or dual antiplatelet therapy, and thrombocytopenia. All the participants were followed up on DAPT following discharge. Specific endpoints including bleeding events, stent thrombosis, stroke and other adverse cardiovascular events were assessed. The latest version of the RevMan software was used for the statistical assessment. Odd ratios (OR) with 95% confidence intervals (CI) based on a fixed or a random statistical model were used to represent the data graphically.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>A total number of 118,945 participants (from 8 studies) were included with 37,753 suffering from thrombocytopenia at baseline. Our results showed post procedural bleeding (OR: 1.89, 95% CI: 1.16\u20133.07; <jats:italic>P<\/jats:italic>\u2009=\u20090.01), access site bleeding (OR: 1.66, 95% CI: 1.15\u20132.39; <jats:italic>P<\/jats:italic>\u2009=\u20090.006), intra-cranial bleeding (OR: 1.78, 95% CI: 1.30\u20132.43; <jats:italic>P<\/jats:italic>\u2009=\u20090.0003), gastro-intestinal bleeding (OR: 1.44, 95% CI: 1.14\u20131.82; <jats:italic>P<\/jats:italic>\u2009=\u20090.002) and any major bleeding (OR: 1.67, 95% CI: 1.42\u20131.97; <jats:italic>P<\/jats:italic>\u2009=\u20090.00001) to be significantly higher in thrombocytopenic patients treated with DAPT after PCI. Total stroke (OR: 1.45, 95% CI: 1.18\u20131.78; <jats:italic>P<\/jats:italic>\u2009=\u20090.0004) specifically hemorrhagic stroke (OR: 1.67, 95% CI: 1.30\u20132.14; <jats:italic>P<\/jats:italic>\u2009=\u20090.0001) was also significantly higher in these patients with thrombocytopenia at baseline. All-cause mortality and major adverse cardiac events were also significantly higher. However, overall total stent thrombosis (OR: 1.18, 95% CI: 0.90\u20131.55; <jats:italic>P<\/jats:italic>\u2009=\u20090.24) including definite and probable stent thrombosis were not significantly different compared to the control group.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>According to the results of this analysis, DAPT might have to be cautiously be used following PCI in a population of patients with thrombocytopenia at baseline due to the significantly higher bleeding rate including gastro-intestinal, intra-cranial bleeding and hemorrhagic stroke. Hence, special care might have to be taken when considering anti-platelet agents following PCI in these high risk patients. However, considering the present limitations of this analysis, this hypothesis will have to be confirmed in future trials.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s40360-020-00409-2","type":"journal-article","created":{"date-parts":[[2020,4,25]],"date-time":"2020-04-25T19:02:56Z","timestamp":1587841376000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Dual anti-platelet therapy following percutaneous coronary intervention in a population of patients with thrombocytopenia at baseline: a meta-analysis"],"prefix":"10.1186","volume":"21","author":[{"given":"Manyun","family":"Long","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziliang","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wuxian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,4,25]]},"reference":[{"issue":"1","key":"409_CR1","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1067\/mhj.2000.106615","volume":"140","author":"DJ Kereiakes","year":"2000","unstructured":"Kereiakes DJ, Berkowitz SD, Lincoff AM, Tcheng JE, Wolski K, Achenbach R, Melsheimer R, Anderson K, Califf RM, Topol EJ. Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb\/IIIa blockade. Am Heart J. 2000;140(1):74\u201380.","journal-title":"Am Heart J"},{"key":"409_CR2","doi-asserted-by":"crossref","unstructured":"Dauerman HL. Anticoagulation strategies for primary percutaneous coronary intervention: current controversies and recommendations. Circ Cardiovasc Interv. 2015;8(5).","DOI":"10.1161\/CIRCINTERVENTIONS.115.001947"},{"key":"409_CR3","doi-asserted-by":"crossref","unstructured":"Deharo P, Cuisset T. Optimal duration of dual antiplatelet therapy post percutaneous coronary intervention in acute coronary syndrome. Trends Cardiovasc Med. 2020;30(4):198-202.","DOI":"10.1016\/j.tcm.2019.05.008"},{"issue":"2","key":"409_CR4","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.ahj.2010.11.001","volume":"161","author":"DA Hakim","year":"2011","unstructured":"Hakim DA, Dangas GD, Caixeta A, Nikolsky E, Lansky AJ, Moses JW, Claessen B, Sanidas E, White HD, Ohman EM, Manoukian SV, Fahy M, Mehran R, Stone GW. Impact of baseline thrombocytopenia on the early and late outcomes after ST-elevation myocardial infarction treated with primary angioplasty: analysis from the harmonizing outcomes with revascularization and stents in AcuteMyocardial infarction (HORIZONS-AMI) trial. Am Heart J. 2011;161(2):391\u20136.","journal-title":"Am Heart J"},{"issue":"2","key":"409_CR5","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s11239-007-0082-0","volume":"25","author":"C Doesch","year":"2008","unstructured":"Doesch C, Kr\u00e4mer B, Geisler T, May AE, Kroeber SM, Kandolf R, Gawaz M. Challenges in the treatment of patients with essential thrombocythemia and acute coronary syndrome. J Thromb Thrombolysis. 2008;25(2):193\u20137.","journal-title":"J Thromb Thrombolysis"},{"issue":"47","key":"409_CR6","doi-asserted-by":"publisher","first-page":"3488","DOI":"10.1093\/eurheartj\/ehx531","volume":"38","author":"CP McCarthy","year":"2017","unstructured":"McCarthy CP, Steg G, Bhatt DL. The management of antiplatelet therapy in acute coronary syndrome patients with thrombocytopenia: a clinical conundrum. Eur Heart J. 2017;38(47):3488\u201392.","journal-title":"Eur Heart J"},{"issue":"18","key":"409_CR7","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1161\/CIRCULATIONAHA.109.858316","volume":"119","author":"TE Warkentin","year":"2009","unstructured":"Warkentin TE, Crowther MA. Adverse prognostic significance of thrombocytopenia in acute coronary syndrome: can anything be done about it? Circulation. 2009;119(18):2420\u20132.","journal-title":"Circulation."},{"issue":"18","key":"409_CR8","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1016\/j.jcin.2018.05.033","volume":"11","author":"K Ayoub","year":"2018","unstructured":"Ayoub K, Marji M, Ogunbayo G, Masri A, Abdel-Latif A, Ziada K, Vallurupalli S. Impact of chronic thrombocytopenia on in-hospital outcomes after PercutaneousCoronary intervention. JACC Cardiovasc Interv. 2018;11(18):1862\u20138.","journal-title":"JACC Cardiovasc Interv"},{"issue":"11","key":"409_CR9","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1016\/j.amjcard.2018.02.010","volume":"121","author":"S Ito","year":"2018","unstructured":"Ito S, Watanabe H, Morimoto T, Yoshikawa Y, et al. Impact of baseline thrombocytopenia on bleeding and mortality after percutaneous coronary intervention. Am J Cardiol. 2018;121(11):1304\u201314.","journal-title":"Am J Cardiol"},{"issue":"4","key":"409_CR10","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.amjcard.2013.04.007","volume":"112","author":"T Kiviniemi","year":"2013","unstructured":"Kiviniemi T, Karjalainen P, Rubboli A, Schlitt A, Tuomainen P, Niemel\u00e4 M, Laine M, Biancari F, Lip GY, Airaksinen KE. Thrombocytopenia in patients with atrial fibrillation on oral anticoagulation undergoing percutaneous coronary intervention. Am J Cardiol. 2013;112(4):493\u20138.","journal-title":"Am J Cardiol"},{"issue":"S1","key":"409_CR11","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1002\/ccd.28030","volume":"93","author":"S Liu","year":"2019","unstructured":"Liu S, Song C, Zhao Y, Guan C, Zhu C, Feng L, Xu B, Dou K. Impact of baseline thrombocytopenia on the long-term outcome of patients undergoing electivepercutaneous coronary intervention: an analysis of 9,897 consecutive patients. Catheter Cardiovasc Interv. 2019;93(S1):764\u201371.","journal-title":"Catheter Cardiovasc Interv"},{"issue":"1","key":"409_CR12","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.ahj.2008.02.003","volume":"156","author":"CB Overgaard","year":"2008","unstructured":"Overgaard CB, Ivanov J, Seidelin PH, Todorov M, Mackie K, Dzav\u00edk V. Thrombocytopenia at baseline is a predictor of in hospital mortality in patients undergoing percutaneous coronary intervention. Am Heart J. 2008;156(1):120\u20134.","journal-title":"Am Heart J"},{"issue":"8","key":"409_CR13","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.mayocp.2016.05.008","volume":"91","author":"CE Raphael","year":"2016","unstructured":"Raphael CE, Spoon DB, Bell MR, et al. Effect of Preprocedural thrombocytopenia on prognosis after percutaneous coronary intervention. Mayo Clin Proc. 2016;91(8):1035\u201344.","journal-title":"Mayo Clin Proc"},{"key":"409_CR14","doi-asserted-by":"publisher","unstructured":"Shiraishi J, Koshi N, Matsubara Y, et al. Effects of baseline thrombocytopenia on in-hospital outcomes in patients undergoing ElectivePercutaneous coronary intervention. Intern Med. 2019. https:\/\/doi.org\/10.2169\/internalmedicine.2063-18.","DOI":"10.2169\/internalmedicine.2063-18"},{"issue":"2","key":"409_CR15","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.cjca.2015.05.020","volume":"32","author":"M Yadav","year":"2016","unstructured":"Yadav M, G\u00e9n\u00e9reux P, Giustino G, et al. Effect of baseline thrombocytopenia on ischemic outcomes in patients with acute CoronarySyndromes who undergo percutaneous coronary intervention. Can J Cardiol. 2016;32(2):226\u201333.","journal-title":"Can J Cardiol"},{"issue":"18","key":"409_CR16","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1016\/j.jacc.2014.01.069","volume":"63","author":"WJ Kikkert","year":"2014","unstructured":"Kikkert WJ, van Geloven N, van der Laan MH, Vis MM, Baan J Jr, Koch KT, Peters RJ, de Winter RJ, Piek JJ, Tijssen JG, Henriques JP. The prognostic value of bleeding academic research consortium (BARC)-defined bleeding complications in ST-segment elevation myocardial infarction: a comparison with the TIMI (Thrombolysis In Myocardial Infarction), GUSTO (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries), and ISTH (International Society on Thrombosis and Haemostasis) bleeding classifications. J Am Coll Cardiol. 2014;63(18):1866\u201375.","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"409_CR17","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1056\/NEJMoa067731","volume":"356","author":"L Mauri","year":"2007","unstructured":"Mauri L, Hsieh WH, Massaro JM, Ho KK, D'Agostino R, Cutlip DE. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med. 2007;356(10):1020\u20139.","journal-title":"N Engl J Med"},{"issue":"9","key":"409_CR18","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","volume":"25","author":"A Stang","year":"2010","unstructured":"Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603\u20135.","journal-title":"Eur J Epidemiol"},{"key":"409_CR19","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, J\u00fcni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA, Cochrane Bias Methods Group; CochraneStatistical Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.","journal-title":"BMJ"},{"key":"409_CR20","doi-asserted-by":"publisher","first-page":"b2700","DOI":"10.1136\/bmj.b2700","volume":"339","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, G\u00f8tzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.","journal-title":"BMJ."},{"issue":"2","key":"409_CR21","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/S0735-1097(98)00252-6","volume":"32","author":"SD Berkowitz","year":"1998","unstructured":"Berkowitz SD, Sane DC, Sigmon KN, Shavender JH, Harrington RA, Tcheng JE, Topol EJ, Califf RM. Occurrence and clinical significance of thrombocytopenia in a population undergoing high-riskpercutaneous coronary revascularization. Evaluation of c7E3 for the prevention of ischemic complications (EPIC) study group. J Am Coll Cardiol. 1998;32(2):311\u20139.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"409_CR22","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1055\/s-0037-1607048","volume":"26","author":"Z Su\u0161ilovi\u0107 Grabovac","year":"2017","unstructured":"Su\u0161ilovi\u0107 Grabovac Z, Bakovi\u0107 D, Lozo M, Pintari\u0107 I, Duji\u0107 \u017d. Early changes in platelet size and number in patients with acute coronary syndrome. Int J Angiol. 2017;26(4):249\u201352.","journal-title":"Int J Angiol"},{"issue":"2","key":"409_CR23","doi-asserted-by":"publisher","first-page":"82","DOI":"10.14712\/18059694.2017.98","volume":"60","author":"FJ Fern\u00e1ndez-Fern\u00e1ndez","year":"2017","unstructured":"Fern\u00e1ndez-Fern\u00e1ndez FJ, Ameneiros-Lago E, Tu\u00f1as-Gesto C, G\u00f3mez-Buela I. Antiplatelet therapy in a patient with coronary artery disease and Myelodysplastic Syndromewith thrombocytopenia. Acta Med (Hradec Kralove). 2017;60(2):82\u20134.","journal-title":"Acta Med (Hradec Kralove)"},{"issue":"1","key":"409_CR24","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/j.1538-7836.2011.04563.x","volume":"10","author":"G Campo","year":"2012","unstructured":"Campo G, Marchesini J, Fileti L, Tebaldi M, Ferrari R. Medical and interventional management of patients with severe thrombocytopenia undergoing percutaneous coronary intervention. J Thromb Haemost. 2012;10(1):153\u20136.","journal-title":"J Thromb Haemost"},{"issue":"21","key":"409_CR25","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1055\/s-0032-1305014","volume":"137","author":"P Staib","year":"2012","unstructured":"Staib P, Forsch S, Niedeggen A, Janssens U. Percutaneous coronary intervention in a patient with acute myeloid leukemia. Dtsch Med Wochenschr. 2012;137(21):1092\u20135.","journal-title":"Dtsch Med Wochenschr"},{"issue":"30","key":"409_CR26","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000016586","volume":"98","author":"J Wang","year":"2019","unstructured":"Wang J, Chen R, Lin X, Wang Y, Wang JH, Wu Y. New perspectives on treatment strategies for patient with acute myeloid leukemia and complex karyotype abnormalities after percutaneous coronary intervention: a case report. Medicine (Baltimore). 2019;98(30):e16586.","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"409_CR27","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/apt.14121","volume":"46","author":"T Krill","year":"2017","unstructured":"Krill T, Brown G, Weideman RA, Cipher DJ, Spechler SJ, Brilakis E, Feagins LA. Patients with cirrhosis who have coronary artery disease treated with cardiac stents have high rates of gastrointestinal bleeding, but no increased mortality. Aliment Pharmacol Ther. 2017;46(2):183\u201392.","journal-title":"Aliment Pharmacol Ther"},{"key":"409_CR28","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.ijcard.2019.11.132","volume":"301","author":"M Bianco","year":"2020","unstructured":"Bianco M, D'ascenzo F, Raposeiras Roubin S, et al. Comparative external validation of the PRECISE-DAPT and PARIS risk scores in 4424 acute coronary syndrome patients treated with prasugrel or ticagrelor. Int J Cardiol. 2020;301:200\u20136.","journal-title":"Int J Cardiol"},{"issue":"14","key":"409_CR29","first-page":"1034","volume":"38","author":"T Palmerini","year":"2017","unstructured":"Palmerini T, Della Riva D, Benedetto U, et al. Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11\u2009473 patients. Eur Heart J. 2017;38(14):1034\u201343.","journal-title":"Eur Heart J"},{"issue":"2","key":"409_CR30","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1002\/ccd.26653","volume":"89","author":"FJ Sawaya","year":"2017","unstructured":"Sawaya FJ, Morice MC, Spaziano M, et al. Short-versus long-term dual antiplatelet therapy after drug-eluting stent implantation in women versus men: a sex-specific patient-level pooled-analysis of six randomized trials. Catheter Cardiovasc Interv. 2017;89(2):178\u201389.","journal-title":"Catheter Cardiovasc Interv"},{"key":"409_CR31","first-page":"2017","volume":"14","author":"T Golden","year":"2017","unstructured":"Golden T, Ghazala S, Wadeea R, Junna S. Abciximab-induced acute profound thrombocytopenia postpercutaneous coronary intervention. BMJ Case Rep. 2017;14:2017.","journal-title":"BMJ Case Rep"},{"issue":"2","key":"409_CR32","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1093\/ehjcvp\/pvu008","volume":"1","author":"JD Wessler","year":"2015","unstructured":"Wessler JD, Giugliano RP. Risk of thrombocytopenia with glycoprotein IIb\/IIIa inhibitors across drugs and patient populations: a meta-analysis of 29 large placebo-controlled randomized trials. Eur Heart J Cardiovasc Pharmacother. 2015;1(2):97\u2013106.","journal-title":"Eur Heart J Cardiovasc Pharmacother"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-020-00409-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-020-00409-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-020-00409-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,25]],"date-time":"2021-04-25T00:02:37Z","timestamp":1619308957000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-020-00409-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,25]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["409"],"URL":"https:\/\/doi.org\/10.1186\/s40360-020-00409-2","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,25]]},"assertion":[{"value":"3 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval was not applicable for this systematic review and meta-analysis.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"31"}}